Pulmonary diffusion abnormalities in patients with inflammatory bowel disease: A longitudinal study.

IF 3.8 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Therapeutic Advances in Gastroenterology Pub Date : 2026-08-03 eCollection Date: 2026-01-01 DOI:10.1177/17562848261475935

Hugo Maisonneuve, Benedicte Caron, Anne Guillaumot, Mathias Poussel, David Sorel, François Chabot, Bruno Ribeiro Baptista, Laurent Peyrin-Biroulet, Ari Chaouat, Simon Valentin

{"title":"Pulmonary diffusion abnormalities in patients with inflammatory bowel disease: A longitudinal study.","authors":"Hugo Maisonneuve, Benedicte Caron, Anne Guillaumot, Mathias Poussel, David Sorel, François Chabot, Bruno Ribeiro Baptista, Laurent Peyrin-Biroulet, Ari Chaouat, Simon Valentin","doi":"10.1177/17562848261475935","DOIUrl":null,"url":null,"abstract":"Background: Impaired diffusing capacity of the lung for carbon monoxide (DLCO) has been frequently described among patients with inflammatory bowel diseases, but longitudinal data of DLCO impairment and its association with IBD activity remain unclear.Objectives: To describe the longitudinal report of prevalence and clinical characteristics of chronic DLCO impairment among patients with IBD reporting respiratory symptoms.Design: We conducted a prospective single-center study including consecutive patients with confirmed IBD and respiratory symptoms.Methods: Patients underwent longitudinal evaluation with chest CT scans and pulmonary function tests.Results: Among 75 patients with DLCO measurements, 12 (16%) showed persistently reduced DLCO over a median follow-up of 26.9 [IQR 24.9-30.6] months. Median DLCO was 63.4% of predicted value. All patients had mild or inactive IBD and were on biologics. Imaging abnormalities were mild and did not explain the DLCO reduction.Conclusions: Chronic DLCO impairment was observed in 16.0% of IBD patients and no obvious association with clinically active IBD was observed in this selected symptomatic cohort.","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261475935"},"PeriodicalIF":3.8000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434094/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848261475935","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Impaired diffusing capacity of the lung for carbon monoxide (DL_CO) has been frequently described among patients with inflammatory bowel diseases, but longitudinal data of DL_CO impairment and its association with IBD activity remain unclear.

Objectives: To describe the longitudinal report of prevalence and clinical characteristics of chronic DL_CO impairment among patients with IBD reporting respiratory symptoms.

Design: We conducted a prospective single-center study including consecutive patients with confirmed IBD and respiratory symptoms.

Methods: Patients underwent longitudinal evaluation with chest CT scans and pulmonary function tests.

Results: Among 75 patients with DL_CO measurements, 12 (16%) showed persistently reduced DL_CO over a median follow-up of 26.9 [IQR 24.9-30.6] months. Median DL_CO was 63.4% of predicted value. All patients had mild or inactive IBD and were on biologics. Imaging abnormalities were mild and did not explain the DL_CO reduction.

Conclusions: Chronic DL_CO impairment was observed in 16.0% of IBD patients and no obvious association with clinically active IBD was observed in this selected symptomatic cohort.

查看原文本刊更多论文

炎症性肠病患者肺弥散异常：一项纵向研究

背景：在炎症性肠病患者中经常描述肺一氧化碳弥散能力受损（DLCO），但DLCO损伤的纵向数据及其与IBD活动的关系尚不清楚。目的：描述在报告呼吸道症状的IBD患者中慢性DLCO损害的患病率和临床特征的纵向报告。设计：我们进行了一项前瞻性单中心研究，包括连续确诊IBD和呼吸道症状的患者。方法：通过胸部CT扫描和肺功能检查对患者进行纵向评估。结果：在75例DLCO测量患者中，12例（16%）在26.9 [IQR 24.9-30.6]个月的中位随访期间DLCO持续降低。中位DLCO为预测值的63.4%。所有患者均为轻度或非活动性IBD，并接受生物制剂治疗。影像学异常轻微，不能解释DLCO降低。结论：16.0%的IBD患者存在慢性DLCO损害，在这一有症状的队列中，未观察到与临床活动性IBD有明显关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.70

自引率

2.40%

发文量

103

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.